(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

World leaders are dismantling global health programs and cutting back foreign aid. Will an extraordinary new medicine be able ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Both Barad and his co-panelist, Joydeep Ganguly, SVP of corporate operations at Gilead Sciences, emphasized that they see AI ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...